May Sonic Hedgehog proteins be markers for malignancy in uterine smooth muscle tumors?

Several studies have demonstrated that the Sonic Hedgehog signaling pathway (SHH) plays an important role in tumorigenesis and cellular differentiation. We analyzed the protein expression of SHH pathway components and evaluated whether their profile could be useful for the diagnosis, prognosis, or prediction of the risk of malignancy for uterine smooth muscle tumors (USMTs). A total of 176 samples (20 myometrium, 119 variants of leiomyoma, and 37 leiomyosarcoma) were evaluated for the protein expression of the SHH signaling components, HHIP1 (SHH inhibitor), and BMP4 (SHE target) by immunohistochemistry. Western blot analysis was performed to verify the specificity of the antibodies. We grouped leiomyoma samples into conventional leiomyomas and unusual leiomyomas that comprise atypical, cellular, mitotically active leiomyomas and uterine smooth muscle tumors of uncertain malignant potential. Immunohistochemical analysis showed that SMO, SUFU, GLIL GLI3, and BMP4 expression gradually increased depending on to the histologic tissue type. The protein expression of SMO, SUFU, and GLI1 was increased in unusual leiomyoma and leiomyosarcoma samples compared to normal myometrium. The inhibitor HHIP1 showed higher expression in myometrium, whereas only negative or basal expression of SMO, SUFU, GLIL and GLI3 was detected in these samples. Strong expression of SHE was associated with poorer overall survival. Our data suggest that the expression of SHH proteins can be useful for evaluating the potential risk of malignancy for USMTs. Moreover, GLI1 and SMO may serve as future therapeutic targets for women with USMTs.

Palavras-chave

Sonic Hedgehog, Immunohistochemistry, Tissue microarray, USMTs, Prognosis

URI

https://observatorio.fm.usp.br/handle/OPI/14316

Referências

Sekiguchi H, 2012, LAB INVEST, V92, P532, DOI 10.1038/labinvest.2012.6
Chiang S, 2013, HISTOPATHOLOGY, V62, P124, DOI 10.1111/his.12048
Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622
Vilos GA, 2012, J MINIM INVAS GYN, V19, P288, DOI 10.1016/j.jmig.2011.12.025
Schwartz PE, 2006, OBSTET GYN CLIN N AM, V33, P183, DOI 10.1016/j.ogc.2005.12.003
Niu YY, 2014, INT J CLIN EXP PATHO, V7, P5144
Kameda C, 2010, BRIT J CANCER, V102, P738, DOI 10.1038/sj.bjc.6605517
Zaitseva M, 2013, REPRODUCTION, V146, P91, DOI 10.1530/REP-13-0087
Li CG, 2015, STEM CELLS, V33, P999, DOI 10.1002/stem.1911
Drenkhahn SK, 2013, CURR CANCER DRUG TAR, V13, P580
Ronci M, 2015, MOL BIOSYST, V11, P1603, DOI 10.1039/c5mb00034c
Okolowsky N, 2014, DEV BIOL, V391, P219, DOI 10.1016/j.ydbio.2014.04.007
Zhao LN, 2014, TOXICOL LETT, V225, P318, DOI 10.1016/j.toxlet.2013.12.022
Fantetti KN, 2012, DEV NEUROBIOL, V72, P1213, DOI 10.1002/dneu.20988
You M, 2014, J THORAC CARDIOV SUR, V147, P508, DOI 10.1016/j.jtcvs.2013.08.035
Choy SW, 2012, VITAM HORM, V88, P1, DOI 10.1016/B978-0-12-394622-5.00001-8
Katoh Y, 2006, INT J MOL MED, V18, P1019
Ip PPC, 2010, ADV ANAT PATHOL, V17, P91, DOI 10.1097/PAP.0b013e3181cfb901
Oliva E, 2014, INT J GYNECOL PATHOL, V33, P374, DOI 10.1097/PGP.0000000000000141
Bian XH, 2014, TUMOR BIOL, V35, P10523, DOI 10.1007/s13277-014-2365-3
Katoh Y, 2009, CURR MOL MED, V9, P873
Choe JY, 2015, J CLIN PATHOL, V68, P6, DOI 10.1136/jclinpath-2014-202434
Choudhry Zia, 2014, Ann Neurosci, V21, P28, DOI 10.5214/ans.0972.7531.210109
Hwang J, 2014, WORLD J SURG ONCOL, V21, P12
Jeng Kuo-Shyang, 2013, Onco Targets Ther, V7, P79, DOI 10.2147/OTT.S54702
Kobayashi H, 2013, MOL CLIN ONCOL, V1, P599
Li TT, 2014, ANN SURG ONCOL, V21, P4164, DOI 10.1245/s10434-014-3888-y
Makharoblidze E, 2013, GEORGIAN MED NEWS, V216, P7
Yang SH, 2013, ONCOLOGY-BASEL, V85, P86, DOI 10.1159/000353452

Coleções

Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo